Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Amgen Inc. is conducting a clinical study titled ‘PROCLAIM: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer.’ The study aims to evaluate the efficacy of romiplostim in treating chemotherapy-induced thrombocytopenia (CIT) by enabling on-time, full-dose chemotherapy administration for patients with NSCLC, ovarian cancer, or breast cancer.
The intervention being tested is Romiplostim, a drug administered via subcutaneous injection, designed to treat CIT in patients undergoing chemotherapy for specific cancers. The study includes a placebo comparator group.
This is a Phase 3 interventional study with a randomized, parallel assignment. It involves quadruple masking, meaning the participant, care provider, investigator, and outcomes assessor are blinded. The primary purpose of the study is treatment.
The study began on February 26, 2020, with an estimated primary completion date and last update submitted on June 25, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
The study’s progress could influence Amgen’s stock performance and investor sentiment, especially if the results show significant efficacy of Romiplostim. This could position Amgen favorably against competitors in the oncology sector.
The study is ongoing, with further details available on the ClinicalTrials portal.